Imported anticancer drugs open price war | Imported anticancer drugs company to grab the market at low prices

Medical Network September 20, after the State Food and Drug Administration speeded up the approval of innovative drugs, imported anti-cancer drugs are running into the Chinese market. Two international pharmaceutical companies have already set up bayonet on the price, want to seize the Chinese market at low prices. On September 18 this year, the manufacturer of PD-1 anti-cancer drug Odivo, Bristol-Myers Squibb, has published the drug price information: 100mg/10ml 9260 yuan (large bottle), 40mg/4ml 4591 yuan (vial). This price is already much cheaper than Taiwan and Hong Kong. However, Merck has announced that its PD-1 inhibitor drug, Pabolizumab, will implement a 'buy three get three' patient assistance program, even though the drug has just been acquired. Granted to China, not yet listed.

PD-1 inhibitor belongs to tumor immunotherapy, and the product is injection. The patient needs intravenous administration, which is mainly used for the treatment of melanoma and non-small cell lung cancer. Bristol-Myers Squibb announced on September 18 this year. Its product, Odivo (Narulisimab injection), has officially landed in the Chinese mainland market for the treatment of adult patients with non-small cell lung cancer. At the same time, Bristol-Myers Squibb officially announced the price information of the product. The price of the product is: 100mg/10ml 9260 yuan, 40mg/4ml 4591 yuan. By comparison, compared with foreign and Hong Kong and Taiwan equivalent drug prices, the price is really a lot cheaper. Previously reported by the media Germany's large bottle of Oddi is 13500-15500 yuan, Taiwan and Hong Kong The price of the drug in the region is 18,000 yuan for the 50ml specification. The patient needs about 3-4 for one treatment.

Merck's PD-1 drug, Pabolizumab injection, with Odivo's foot and foot entering the Chinese market, although the current pricing has not been made public, pharmacy The hospital has not yet started sales, but the company soon announced the introduction of a patient assistance program, which will adopt a three-benefit program. The specific content of the program is that after the patient has used the drug for 3 months, the drug is safe and effective for me, no obvious. Toxic side effects, Merck will give patients free 3 months of assistance drug This program means that this anticancer drug will be half price on a low price basis.

For the price of Merck's Pableyizumab injection, there are market speculations, roughly equivalent to Odivo.

Beijing Youth Daily reporter learned yesterday that Merck's PD-1 drug, Pabolizumab, has been on the market for some time. And Bristol-Myers Squibb's Odivo is in Beijing, Shanghai's big pharmacy is out of stock. Shanghai The sales staff of Zhongxie Pharmacy said that currently Odivo is out of stock, 'It is estimated that there will be a bottle of 9260 yuan for 100ml and 4,591 yuan for 40ml. The mail order of other provinces and cities needs to pay the cold chain transportation fee. From Shanghai to Beijing, the transportation fee is 760 yuan, and the price will be higher in remote areas. 'The above-mentioned person said. Beijing Andingmen Medical Insurance brand new pharmacy sales staff said that now Odivo is out of stock, if you want to buy, only You can register for the waiting notice first. Please bring your doctor's prescription when you buy the medicine. The Beijing area can be delivered to your door free of charge.

According to the customer service staff of Bristol-Myers Squibb, Odivo is a prescription drug. Even if you go to the pharmacy to buy it, you need to be prescribed by a doctor. hospital , Tumor Specialist hospitals can prescribe the drug. It is understood that the use of Odiva injection is intravenous drip, the treatment process needs to be carried out in the hospital to ensure the safety of medication. Therefore, professionals recommend that patients buy drugs in the pharmacy, You should first communicate with your doctor.